- Details
- David Penson joins Alicia Morgans to discuss the rapidly changing landscape in prostate cancer, focusing on how imaging and therapeutic advances have disrupted the landscape in the nonmetastatic castration-resistant prostate cancer (CRPC) setting. Dr. Penson highlights advancements in PSMA scanning and how it impacts potential study inclusion criteria. Drs. Morgans and Penson also discuss PSMA PET...
|
- Details
- Wesley Yip and Sam Chang discuss the results of a multicenter trial of neoadjuvant gemcitabine and cisplatin in patients with upper tract urothelial carcinoma (UTUC) presented at the ASCO GU 2022 Cancer Symposium. This phase II multicenter trial of neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with high-risk UTUC prior to extirpative surgery sought to evaluate major outcomes...
|
- Details
- Sam Chang is joined by Deborah Kaye to discuss the "best papers" in urothelial carcinoma that she highlighted for her presentation at the GU ASCO 2022 Annual Meeting. She highlights four papers on urothelial carcinoma that she selected based on their clinical relevance and how they have a direct impact on bladder cancer patients today. Biographies: Deborah Kaye, MD, MS, Urologic Oncologist, Assist...
|
- Details
- Matthew Cooperberg joins Charles Ryan in a discussion on risk-stratified therapy for localized prostate cancer discussing who the patient is that should get active surveillance (AS) vs who shouldn't. To begin their conversation, Dr. Cooperberg previews the latest data coming from the AUA Quality Registry (AQUA) on the percentage of patients receiving active surveillance. This full data will be pre...
|
- Details
- Alicia Morgans is joined by Brian Gonzalez to discuss work he presented at GU ASCO 2022 on patient-reported quality of life metrics among men receiving prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study being discussed treated 50 patients, between 2015 to 2017, with up to 4 cycles of 177Lu-PSM...
|
- Details
- At the 2022 ASCO GU meeting, Stephen Boorjian chaired a rapid abstract session in urothelial carcinoma focusing on three broad topics in advanced urothelial cancer. One abstract covers the role of neoadjuvant chemotherapy with gemcitabine and cisplatin, for patients with upper tract urothelial carcinoma. One abstract covers maintenance therapy with a checkpoint inhibitor, for patients who've not e...
|
- Details
- Oliver Sartor and Alicia Morgans discuss her recent presentation at GU ASCO 2022 on the results of a study assessing PSA outcomes in black and white chemotherapy-naïve prostate cancer patients treated with enzalutamide. This study assessed real-world PSA outcomes (response and progression) of enzalutamide-treated black vs white patients with prostate cancer patients in the US. Dr. Morgans and coll...
|
- Details
- In this discussion, Neal Shore joins Alicia Morgans in a conversation about a clinical trial for patients with mHSPC, the ARASEC trial. This study is designed to demonstrate how well darolutamide administered together with androgen deprivation therapy works in men with metastatic hormone-sensitive prostate cancer. Biographies: Neal Shore, MD, FACS , is the Medical Director of the Carolina Urologic...
|
- Details
- Axel Merseburger joins Alicia Morgans to discuss the results from the PRESIDE study presented at ASCO GU 2022. PRESIDE is a randomized, double-Blind, placebo-controlled, Phase 3b study of the efficacy and safety of continuing enzalutamide in chemotherapy-naïve, mCRPC patients treated with docetaxel plus prednisolone once they have progressed on enzalutamide. Clinical data demonstrate that using do...
|
- Details
- Alicia Morgans and Pedro Barata highlight real-world data understanding the metastatic prostate cancer setting, capturing data on patients treated for metastatic hormone-sensitive and then metastatic castration-resistant disease presented at ASCO GU 2022. Clinical trials presented over the past seven years have led to novel hormonal therapies as well as taxane based chemotherapy being approved for...
|
